NORDICUS PARTNERS CORPORATION ANNOUNCES KEY MILESTONE IN DEVELOPMENT OF OROCIDIN’S BREAKTHROUGH TREATMENT FOR PERIODONTITIS
BEVERLY HILLS, California—January 14, 2025. Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announced today that its subsidiary, Orocidin A/S, will initiate its toxicity program for Orocidin (QR-01) in January 2025. The program is […]
OROCIDIN’S QR-01 SHOWS POSITIVE RESULTS IN TREATING PERIODONTITIS IN DOGS
BEVERLY HILLS, California—April 2, 2025. Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, today announced positive efficacy results for its lead periodontitis candidate, QR-01, in a preclinical study […]
OROCIDIN AND SYNGENE PARTNER TO ACCELERATE BIOTECH INNOVATION
BEVERLY HILLS, California—February 20, 2025. Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announces a strategic partnership with Syngene International Limited (“Syngene”). Syngene’s mission is to work as […]
OROCIDIN QR-01 SHOWS A GOOD SAFETY PROFILE IN PRECLINICAL TOXICITY STUDY
BEVERLY HILLS, California—February 18, 2025. Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, has successively completed its first toxicity study for QR-01, a novel treatment for aggressive periodontitis.. […]
OROCIDIN LAUNCHES GROUNDBREAKING DENTAL GEL FOR LONG-TERM PERIODONTITIS TREATMENT
BEVERLY HILLS, California—January 28, 2025. Orocidin A/S, a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, has developed a novel, proprietary dental gel that represents a significant breakthrough in the long-term treatment […]
NORDICUS PARTNERS CORPORATION ACQUIRES THE REMAINING 5% SHARES IN OROCIDIN A/S
Beverly Hills, California. November 12, 2024…Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, today announced it has entered into an agreement with Orocidin A/S (“Orocidin”) to acquire the remaining approximately 5% […]
OROCIDIN – NEW INSIGHTS INTO THE TREATMENT OF PERIODONTITIS
Beverly Hills, California. June 11, 2024…Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, and its 95% owned subsidiary, Orocidin A/S (“Orocidin”), announced today new insights into the treatment of periodontitis. Orocidin’s […]
NORDICUS PARTNERS CORPORATION ACQUIRES 95% STAKE IN OROCIDIN A/S
Beverly Hills, California. May 15, 2024…Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. Life Sciences companies with optimal conditions to establish themselves on the U.S. market, announced today that it has entered into an agreement with Orocidin A/S (“Orocidin”) to acquire a 95% stake […]
NORDICUS PARTNERS CORPORATION ENTERS INTO A CONSULTANCY AGREEMENT WITH OROCIDIN A/S IN DENMARK
Beverly Hills, California., Jan. 10, 2024… Nordicus Partners Corporation (OTC PINK: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. Life Sciences companies with optimal conditions to establish themselves on the U.S. market, today announced it entered into a paying Consultancy Agreement with Orocidin A/S in Denmark. Orocidin A/S (“Orocidin”) […]